Hansoh Pharmaceutical Group Co Limited/ADR
HNPHYN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 31, 2026
18wMarket Overview
Stock performance and key metrics
HNPHY News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
HS-20093
Metastasis Castration Resistant Prostate Cancer(mCRPC)
Gemcitabine combined with docetaxel
Osteosarcoma
HS-20089
Ovarian Cancer
HS-10542
Paroxysmal Nocturnal Hemoglobinuria
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HS-20093 | Phase 3 | Metastasis Castration Resistant Prostate Cancer(mCRPC) | - | - |
Gemcitabine combined with docetaxel | Phase 3 | Osteosarcoma | - | - |
HS-20089 | Phase 2 | Ovarian Cancer | - | - |
HS-10542 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply